Compare Pfizer Inc (PFE) vs Unilever plc (UL) Price & Performance

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Unilever (UL) trades at $63.54, down 1.03% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $50.50 billion in 2025, with a net income margin of 18.32% and strong profitability metrics like ROE of 54.57%. Recent news highlights strategic partnerships in AI and a narrowed lawsuit with Ben & Jerry's, while Q2 2026 earnings showed 5.8% underlying sales growth, the strongest in a decade (Reuters, 2026-07-28).

Outlook is mixed: robust emerging market exposure and cost discipline support growth, but earnings misses and a net cash outflow of -$2.08 billion in 2025 pose risks. Analyst consensus is neutral with 51.36% hold ratings, reflecting cautious optimism amid execution challenges from portfolio simplification and competitive pressures.